Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)

Name: Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)
Published: 2005
License: Public Domain

Amgen · 2005

ClinicalTrials.gov · Datasets · License: Public Domain · 2005

Open Source ↗

clinical-trials rheumatoid-arthritis

rheumatoid arthritis, rheumatoid arthritis, ra, enbrel® (etanercept), clinical trials, amgen, immunex, methotrexate (mtx), rheumatoid arthritis (ra), interventional, phase4

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)

Related documents